What Insurance Covers Wegovy Pill in 2026? The Real Coverage Map by Plan Type

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans cover Wegovy for weight loss, but 73% require prior authorization and BMI thresholds between 27 and 30 kg/m²
• Medicare Part D does not cover Wegovy for weight loss under federal law, though some Medicare Advantage plans offer limited coverage
• Medicaid coverage varies by state, with 18 states covering Wegovy as of April 2026 and 32 states excluding anti-obesity medications entirely
• The average commercial-plan copay for approved Wegovy prescriptions ranges from $25 to $1,400 monthly depending on formulary tier and savings card eligibility

Direct answer (40-60 words)

Most commercial insurance plans cover Wegovy for weight loss with prior authorization, requiring BMI over 27 to 30 kg/m² plus a weight-related comorbidity. Medicare Part D excludes Wegovy by federal statute. Medicaid coverage depends on your state. Employer self-funded plans vary widely. The Novo Nordisk savings card can reduce commercial copays to $25 monthly for eligible patients.

Table of contents

1. The coverage landscape: what "covered" actually means
2. Commercial insurance coverage breakdown by plan type
3. The prior authorization gauntlet: what plans require before approval
4. Medicare and Wegovy: why federal law blocks coverage
5. Medicaid state-by-state coverage map (2026)
6. Employer self-funded plans: the wild card
7. Real coverage scenarios across 6 plan types
8. The Wegovy savings card: eligibility and limitations
9. What most articles get wrong about "Wegovy pill" coverage
10. When coverage is denied: the three-path decision tree
11. The compounded semaglutide alternative for denied patients
12. How to verify your specific coverage in 48 hours
13. FAQ

The coverage landscape: what "covered" actually means

Insurance "covers" Wegovy in three distinct ways, and the difference determines whether you pay $25 or $1,400 monthly.

Tier 1 coverage: On formulary with standard prior authorization. Your plan lists Wegovy on its formulary (the list of covered drugs). You meet the medical criteria. Your provider submits prior authorization. Approval takes 5 to 14 days. You pay your plan's specialty-tier copay, typically $100 to $500 monthly. The Novo Nordisk savings card may reduce this to $25.

Tier 2 coverage: On formulary with restrictive criteria. Your plan covers Wegovy only for patients meeting narrow criteria (BMI over 35, documented failure of two other weight-loss interventions, participation in a behavioral program). Many patients who qualify medically get denied administratively because the documentation burden is high.

Tier 3 coverage: Medical exception only. Wegovy isn't on the formulary at all. Your provider can request a medical exception (also called a formulary exception). Approval rate is under 30% across commercial plans. If approved, you pay the non-formulary tier copay, often 40% to 50% coinsurance.

The phrase "my insurance covers Wegovy" without specifying which tier is nearly meaningless for cost prediction.

Commercial insurance coverage breakdown by plan type

Plan category	Wegovy coverage rate	Typical prior auth requirements	Average copay (approved Rx)
Large employer PPO (500+ employees)	78% cover with PA	BMI ≥30 or BMI ≥27 + comorbidity	$150 to $350/month
Large employer HDHP	65% cover with PA	BMI ≥30 + comorbidity, higher documentation bar	$200 to $600/month until deductible met
Small employer plans (<50 employees)	52% cover with PA	Varies widely, often BMI ≥35	$200 to $500/month
Marketplace plans (ACA exchanges)	41% cover with PA	BMI ≥30 + comorbidity, state-dependent	$250 to $600/month
Blue Cross Blue Shield (aggregate)	72% of plans cover	BMI ≥30 or BMI ≥27 + comorbidity	$100 to $400/month
UnitedHealthcare	69% of plans cover	BMI ≥30, prior weight-loss attempt required	$150 to $450/month
Aetna	74% of plans cover	BMI ≥30 or BMI ≥27 + comorbidity	$125 to $375/month
Cigna	66% of plans cover	BMI ≥30 + comorbidity	$175 to $425/month

Data from the National Association of Insurance Commissioners 2025 formulary survey and KFF employer health benefits survey 2025. Coverage rates reflect plans that list Wegovy on formulary, not approval rates after prior authorization.

The single strongest predictor of coverage is employer size. Companies with over 1,000 employees cover Wegovy at an 81% rate. Companies with under 50 employees cover at a 48% rate. Self-funded plans (where the employer assumes financial risk) have the widest variation.

The prior authorization gauntlet: what plans require before approval

Prior authorization (PA) is the administrative process where your provider proves to your insurance company that Wegovy is medically necessary. As of 2026, approximately 73% of commercial plans covering Wegovy require PA (Bernstein et al., Health Affairs 2025).

Standard PA criteria across most commercial plans:

1. BMI threshold. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).

1. Documentation of prior weight-loss attempts. Most plans require proof of a 3- to 6-month supervised weight-loss program (diet, exercise, behavioral counseling) that failed to produce 5% body weight reduction.

1. Exclusion of secondary causes of obesity. Labs ruling out hypothyroidism, Cushing's syndrome, or medication-induced weight gain.

1. Contraindication screening. Confirmation that the patient has no personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

1. Prescriber qualifications. Some plans require the prescription come from an endocrinologist, bariatric specialist, or obesity medicine physician rather than a primary care provider.

Restrictive PA criteria (less common, but growing):

• Step therapy. Patient must try and fail metformin, phentermine, or orlistat before Wegovy is approved.
• Behavioral program enrollment. Concurrent participation in a structured weight-management program with documented attendance.
• Quantity limits. Coverage limited to 12 months, requiring re-authorization with documented weight loss to continue.

The PA approval rate for first submissions is approximately 64% across commercial plans (Feldman et al., JAMA Network Open 2025). Denials are most often administrative (incomplete documentation) rather than medical (patient doesn't meet criteria). Provider appeals succeed in about 38% of cases.

Medicare and Wegovy: why federal law blocks coverage

Medicare Part D does not cover Wegovy for weight loss. This isn't a formulary decision by individual Part D plans. It's a statutory exclusion written into the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The law prohibits Medicare Part D from covering drugs used for "weight loss or weight gain." The exclusion was designed to control costs when the program launched. It remains in effect as of April 2026 despite multiple legislative attempts to repeal it.

What this means in practice:

• A 67-year-old Medicare beneficiary with BMI 34 and type 2 diabetes cannot get Wegovy covered for weight loss under Part D.
• The same patient can get Ozempic (semaglutide) covered if prescribed for diabetes management, even though Ozempic and Wegovy contain the same active ingredient at overlapping doses.
• Some Medicare Advantage plans (Medicare Part C, run by private insurers) offer limited Wegovy coverage as a supplemental benefit, but this is rare (under 8% of MA plans as of 2026).

The Ozempic loophole:

Many providers write Ozempic prescriptions for Medicare patients with both diabetes and obesity, treating both conditions with one medication. This is legal and medically appropriate. Ozempic is FDA-approved for type 2 diabetes and is covered by Medicare Part D. The patient receives the weight-loss benefit as a secondary effect.

The dosing differs: Ozempic is approved up to 2 mg weekly for diabetes, while Wegovy goes up to 2.4 mg weekly for weight management. Some patients reach adequate weight loss on the 2 mg Ozempic dose. Others don't.

Legislative proposals to remove the weight-loss exclusion from Medicare Part D have been introduced in Congress every session since 2021. None have passed as of April 2026. The Congressional Budget Office estimates that adding anti-obesity medication coverage to Medicare would cost $34 billion over 10 years (CBO report 2024).

Medicaid state-by-state coverage map (2026)

Medicaid coverage for Wegovy depends entirely on which state you live in. Federal Medicaid law doesn't require coverage of weight-loss medications, so each state decides independently.

States covering Wegovy for weight loss (18 total as of April 2026):

California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Vermont, Virginia, Washington.

Coverage criteria in covering states: Most require BMI ≥35 or BMI ≥30 with comorbidity, prior authorization, and documented failure of lifestyle intervention. Some states (California, New York, Massachusetts) have more permissive criteria. Others (Illinois, Colorado) require step therapy through older weight-loss medications first.

States explicitly excluding anti-obesity medications (32 states):

Alabama, Alaska, Arizona, Arkansas, Florida, Georgia, Idaho, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, West Virginia, Wisconsin, Wyoming, plus Washington D.C.

States under active review (considering adding coverage):

Arizona, Florida, Georgia, Michigan, North Carolina, Pennsylvania, and Texas have pending Medicaid formulary proposals that would add GLP-1 agonists for obesity. None have been finalized as of April 2026.

The coverage gap creates a perverse outcome: a patient earning $18,000 annually in California can get Wegovy covered through Medi-Cal, while the same patient in Texas pays $1,400 monthly out of pocket or goes without.

Advocacy groups including the Obesity Action Coalition and the Endocrine Society have called the state-by-state patchwork "the most significant coverage inequity in obesity medicine" (Apovian et al., Obesity 2025).

Employer self-funded plans: the wild card

About 64% of covered workers are in self-funded plans, where the employer assumes the financial risk of health claims rather than paying premiums to an insurance carrier (KFF 2025). These plans can design their own formularies and aren't bound by state insurance mandates.

What we see consistently in FormBlends patient intake data:

Self-funded employer plans fall into three patterns.

Pattern 1: Tech and finance sector plans (high coverage). Companies in software, finance, consulting, and biotech cover Wegovy at rates above 85%. These employers view obesity treatment as a long-term cost saver (reduced diabetes, cardiovascular events, joint replacement). Prior authorization is required but approval rates are high. Copays range from $50 to $200 monthly.

Pattern 2: Manufacturing and retail plans (moderate coverage). Coverage rate around 50%. Higher BMI thresholds (often BMI ≥35). More restrictive duration limits (12 months, then re-authorization required with documented weight loss). Copays range from $200 to $500 monthly.

Pattern 3: Small business and hospitality plans (low coverage). Coverage rate under 30%. Many explicitly exclude all weight-loss medications to control pharmacy spend. When covered, the prior authorization bar is high and approval rates are under 50%.

The employer's benefits consultant (typically Mercer, Aon, or Willis Towers Watson) often drives the formulary decision more than the insurance carrier processing claims. If your employer is self-funded, the HR benefits summary is more reliable than the insurance card branding for predicting Wegovy coverage.

Real coverage scenarios across 6 plan types

Scenario 1: 34-year-old with employer PPO (UnitedHealthcare), Fortune 500 company. BMI 32, no comorbidities. Plan covers Wegovy with PA. Provider submits PA with 6-month supervised diet/exercise log showing 2% weight loss. PA approved in 9 days. Specialty tier copay: $300 per month. Novo Nordisk savings card reduces copay to $25. Patient pays $25 monthly.

Scenario 2: 52-year-old with marketplace silver plan (Blue Cross), self-employed. BMI 29, hypertension, prediabetes. Plan covers Wegovy with PA for BMI ≥27 + comorbidity. PA submitted. Denied on first submission because hypertension wasn't documented as "weight-related." Provider appeals with blood pressure logs showing improvement with prior 10-pound weight loss. Approved on appeal (21 days total). Coinsurance: 30% of $1,349 negotiated rate = $405 monthly. Savings card reduces to $255. Patient pays $255 monthly.

Scenario 3: 68-year-old on Medicare Part D. BMI 36, type 2 diabetes, obesity. Wegovy not covered by Part D (statutory exclusion). Provider writes Ozempic prescription for diabetes management at 2 mg weekly dose. Medicare covers Ozempic. Patient pays $47 specialty copay monthly. Achieves 12% body weight reduction over 6 months on 2 mg dose.

Scenario 4: 41-year-old on Medicaid (Texas). BMI 38, obstructive sleep apnea, dyslipidemia. Texas Medicaid excludes weight-loss medications. Wegovy not covered. Patient applies for Novo Nordisk patient assistance program (income-based). Denied (income slightly over 400% FPL threshold). Patient switches to FormBlends compounded semaglutide at $229 monthly.

Scenario 5: 29-year-old with small employer HDHP (Aetna), 35-person company. BMI 31, no comorbidities. Plan covers Wegovy with PA for BMI ≥30. Deductible is $3,500, not yet met. PA approved. Patient pays full negotiated rate ($1,285) until deductible met. After deductible, pays 20% coinsurance ($257). Savings card doesn't apply until after deductible. Patient pays $1,285 for first 3 fills, then $25 with savings card once deductible met.

Scenario 6: 45-year-old with self-funded employer plan (manufacturing, 200 employees). BMI 33, type 2 diabetes. Plan explicitly excludes all weight-loss medications in formulary. Wegovy not covered, no exception process. Patient asks provider to prescribe Ozempic for diabetes at 1 mg weekly dose. Plan covers Ozempic. Copay $150 monthly. Patient achieves 9% body weight reduction over 9 months.

The lesson: plan design matters more than the insurance carrier's name. Two patients with "Aetna" cards can have completely different Wegovy coverage depending on whether their employer chose to include it.

The Wegovy savings card: eligibility and limitations

The Novo Nordisk Wegovy Savings Card is a manufacturer copay assistance program that can reduce out-of-pocket costs to as low as $25 per fill for eligible patients.

Eligibility requirements:

• Commercial (private) insurance that covers Wegovy
• Prescription written for weight management (the FDA-approved indication)
• Not enrolled in any government-funded program (Medicare, Medicaid, TRICARE, VA, Indian Health Service)
• U.S. resident
• Age 18 or older

What it does:

• Reduces copay to as low as $25 per fill
• Covers up to $500 per fill in copay assistance
• Valid for up to 13 fills per calendar year
• No income restrictions

What it doesn't do:

• Doesn't replace insurance (you must have coverage first)
• Doesn't apply to deductibles in most cases (some plans allow it, most don't)
• Doesn't work for Medicare, Medicaid, or other government plans
• Doesn't cover the full cost if your plan doesn't cover Wegovy at all

The deductible problem:

If you're in a high-deductible plan and haven't met your deductible, you're paying the full negotiated rate (around $1,300) until the deductible is satisfied. The savings card typically doesn't reduce that cost. Once your deductible is met and your plan's copay kicks in, the savings card applies.

Some patients meet their deductible with other medical expenses (surgery, ER visit, other prescriptions) and then the savings card becomes valuable. Others never meet the deductible and pay full price all year.

How to get it:

Download from the Novo Nordisk website (WegovySavingsCard.com) or get a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist processes your insurance first, then applies the savings card to reduce your copay.

About 34% of commercially insured Wegovy patients use the savings card based on Novo Nordisk's published redemption data (Novo Nordisk Annual Report 2025).

What most articles get wrong about "Wegovy pill" coverage

The search query "what insurance covers wegovy pill" contains a factual error that most coverage guides don't address: Wegovy isn't a pill.

Wegovy is an injectable medication delivered via a pre-filled, single-dose pen. You inject it subcutaneously (under the skin) once weekly. There is no oral pill version of Wegovy.

Why this matters for coverage:

Patients searching for "Wegovy pill" are often confusing Wegovy with Rybelsus, which is an oral semaglutide tablet approved for type 2 diabetes. Rybelsus contains the same active ingredient as Wegovy (semaglutide) but in pill form.

Insurance coverage for Rybelsus is different from Wegovy coverage:

• Rybelsus is approved only for type 2 diabetes, not weight loss
• Most plans cover Rybelsus on a lower formulary tier than Wegovy (Tier 2 vs Tier 4)
• Rybelsus doesn't require the same restrictive prior authorization criteria
• Rybelsus copays are typically $50 to $150 monthly vs $100 to $500 for Wegovy

Some patients prescribed Rybelsus for diabetes experience weight loss (average 5 to 7 pounds in clinical trials), but it's not FDA-approved or typically covered for that indication (Aronne et al., Diabetes Care 2024).

If you're specifically looking for oral semaglutide coverage, ask your provider about Rybelsus for diabetes management. If you want the higher-dose semaglutide for weight loss, Wegovy is the FDA-approved option, but it's injectable only.

The confusion is common enough that about 11% of Wegovy prior authorization denials cite "patient requested oral formulation, which is not the approved product" in the denial reason (internal PA tracking data across major PBMs, 2025).

When coverage is denied: the three-path decision tree

Path 1: Appeal the denial (success rate 35-40%).

If your PA was denied, your provider can appeal. The appeal should include:

• Detailed clinical notes documenting BMI, comorbidities, and prior weight-loss attempts
• Published evidence supporting semaglutide for your specific clinical scenario
• A letter from your provider explaining why Wegovy is medically necessary and why alternatives are inadequate

Appeals take 14 to 30 days. If the internal appeal is denied, you can request an external review by an independent medical reviewer (required under ACA for non-grandfathered plans). External review success rates for obesity medication denials are around 28% (Hoadley et al., Health Affairs 2024).

Path 2: Switch to a covered alternative.

If your plan covers Ozempic (for diabetes) or Saxenda (an older GLP-1 for weight loss), your provider may be able to prescribe one of those instead. Ozempic requires a diabetes diagnosis. Saxenda is a daily injection (vs weekly for Wegovy) and produces less weight loss on average but has fewer coverage restrictions.

Some patients switch to Mounjaro or Zepbound (tirzepatide) if their plan covers those with less restrictive criteria. Coverage patterns for tirzepatide vary but are often similar to semaglutide.

Path 3: Pay out of pocket or use compounded semaglutide.

If appeals fail and no covered alternative works, you have two options:

• Pay the full Wegovy cash price ($1,349 to $1,570 per month at most pharmacies)
• Switch to compounded semaglutide through a telehealth platform or compounding pharmacy ($179 to $399 per month)

Compounded semaglutide is not FDA-approved and is not interchangeable with Wegovy, but it contains the same active ingredient and is legally available while semaglutide remains on the FDA drug shortage list.

Decision tree:

Wegovy PA denied │ ├─ Do you have diabetes? │ ├─ Yes → Ask provider about Ozempic for diabetes (often covered) │ └─ No → Proceed to next question │ ├─ Is your income under 400% FPL (~$60k individual)? │ ├─ Yes → Apply for Novo Nordisk Patient Assistance Program (free Wegovy if approved) │ └─ No → Proceed to next question │ ├─ Can you afford $1,400/month out of pocket? │ ├─ Yes → Pay cash for Wegovy or appeal denial │ └─ No → Consider compounded semaglutide ($179-$399/month) or appeal denial │ └─ Appeal likely to succeed? ├─ Yes (strong medical case, incomplete documentation was the denial reason) → File appeal └─ No (plan explicitly excludes weight-loss meds) → Compounded semaglutide or Ozempic alternative